Read by QxMD icon Read

Prostate Cancer and Prostatic Diseases

Karen S Sfanos, Mark C Markowski, Lauren B Peiffer, Sarah E Ernst, James R White, Kenneth J Pienta, Emmanuel S Antonarakis, Ashley E Ross
BACKGROUND: It is well known that the gastrointestinal (GI) microbiota can influence the metabolism, pharmacokinetics, and toxicity of cancer therapies. Conversely, the effect of cancer treatments on the composition of the GI microbiota is poorly understood. We hypothesized that oral androgen receptor axis-targeted therapies (ATT), including bicalutamide, enzalutamide, and abiraterone acetate, may be associated with compositional differences in the GI microbiota. METHODS: We profiled the fecal microbiota in a cross-sectional study of 30 patients that included healthy male volunteers and men with different clinical states of prostate cancer (i...
July 9, 2018: Prostate Cancer and Prostatic Diseases
Michael Austin Coker, Zachary A Glaser, Jennifer B Gordetsky, John V Thomas, Soroush Rais-Bahrami
BACKGROUND: Magnetic resonance imaging (MRI)/ultrasound (US) fusion-guided biopsy has improved the ability to localize and detect prostate cancer (PCa) with efficiency surpassing systematic biopsy. Nevertheless, some patients have PCa missed using the MRI-targeted biopsy sampling alone. We aim to identify clinical and imaging parameters associated with cases where targeted biopsy did not detect PCa compared to systematic biopsy. METHODS: We conducted a retrospective review of patients who underwent MRI/US fusion-guided biopsy in addition to concurrent systematic, extended-sextant biopsy between 2014 and 2017...
July 9, 2018: Prostate Cancer and Prostatic Diseases
Kurt Miller, Günther G Steger, Daniela Niepel, Diana Lüftner
BACKGROUND: Patients with prostate cancer are at risk of impaired bone health. Prostate cancer has a propensity to metastasize to bone, after which patients are at risk of skeletal-related events (SREs). These complications are associated with increased mortality, substantial pain, and reduced quality of life. Patients are also at risk of bone loss due to androgen deprivation therapy (ADT), which can be compounded in elderly patients with reduced bone density. It is essential, therefore, that aspects of bone health and therapies able to prevent the occurrence of SREs are considered throughout the clinical course of prostate cancer...
July 9, 2018: Prostate Cancer and Prostatic Diseases
Zhenlang Guo, Yiyu Huang, Leiliang Gong, Shu Gan, Franky Leung Chan, Chiming Gu, Songtao Xiang, Shusheng Wang
BACKGROUND: Whether androgen deprivation therapy (ADT) causes excess thromboembolic events (TEs) in men with prostate cancer (PCa) remains controversial and is the subject of the US Food and Drug Administration safety warning. This study aims to perform a systematic review and meta-analysis on previous studies to determine whether ADT is associated with TEs in men with PCa. METHODS: Medline, Embase, and Cochrane Library databases were searched for relevant studies...
July 9, 2018: Prostate Cancer and Prostatic Diseases
Muammer Altok, Bumyang Kim, Bina B Patel, Ya-Chen Tina Shih, John F Ward, Stephen E McRae, Brian F Chapin, Louis L Pisters, Curtis A Pettaway, Jeri Kim, Huseyin C Demirel, John W Davis
BACKGROUND: The cornerstone of prostate cancer diagnosis remains the transrectal ultrasound-guided biopsy (TRUS-BX), which most frequently occurs in the office setting under local anesthesia. However, there are now other techniques of prostate biopsy aimed at improving outcomes such as patient comfort, significant cancer detection, and infectious complications. The purpose of the present study is to compare the cost and efficacy outcomes of five different approaches. METHODS: We compared the comprehensive costs of a random sample size of 20-30 cases from each of the following: (1) local anesthesia TRUS-BX (reference), (2) sedation TRUS-BX, (3) general anesthesia transperineal template biopsy (TP), (4) sedation MRI-TRUS fusion biopsy (FB), and (5) sedation in-bore MRI biopsy (IB-MRI)...
July 9, 2018: Prostate Cancer and Prostatic Diseases
Jonathan E Katz, Felix M Chinea, Vivek N Patel, Raymond R Balise, Vivek Venkatramani, Mark L Gonzalgo, Chad Ritch, Alan Pollack, Dipen J Parekh, Sanoj Punnen
BACKGROUND: Non-Hispanic Black (NHB) men are at an increased risk for aggressive prostate cancer (PCa), making active surveillance (AS) potentially less optimal in this population. This concern has not been explored in other minority populations-specifically, Hispanic/Latino men. We recently found that Mexican-American men demonstrate an increased risk of PCa-specific mortality, and we hypothesized that they may also be at risk for an adverse outcome on AS. METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) program, we extracted a population-based cohort of men diagnosed from 2004 to 2013 with localized or regional PCa, who had ≤2 cores of only Grade Group (GG) 1 cancer, and underwent radical prostatectomy (RP) with available biopsy and surgical pathology results...
July 9, 2018: Prostate Cancer and Prostatic Diseases
Viranda H Jayalath, Madhur Nayan, Antonio Finelli, Maria Komisarenki, Narhari Timilshina, Girish S Kulkarni, Neil E Fleshner, Bimal Bhindi, Andrew Evans, Alexandre R Zlotta, Robert J Hamilton
PURPOSE: Recent evidence suggests that statins may improve prostate cancer outcomes; however, their role in active surveillance (AS) is poorly characterized. We aimed to evaluate the association between statin use at diagnosis and time to progression on AS. MATERIALS AND METHODS: Data were obtained from a prospectively maintained cohort of men undergoing AS between 1995 and 2016 at our institution. All men satisfied the low-risk criteria: Gleason score <7, <4 positive cores, <50% involvement of any core, and prostate-specific antigen level <10...
June 6, 2018: Prostate Cancer and Prostatic Diseases
Pui San Tan, Pedro Aguiar, Benjamin Haaland, Gilberto Lopes
BACKGROUND: Patients with metastatic prostate cancer have poor prognosis. In this study, we compared the addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to standard ADT vs. ADT alone for patients with mHSPC in terms of overall survival (OS), failure-free survival (FFS), and adverse events. METHODS: We searched PubMed and performed a network meta-analysis to generate probabilistic inferences and provide efficacy rankings in terms of posterior hazard ratios with 95% credible intervals (CrI), surface under the cumulative ranking curve (SUCRA), probability better than competing treatments, and probability best...
June 6, 2018: Prostate Cancer and Prostatic Diseases
De Nunzio Cosimo, Brassetti Aldo, Simone Giuseppe, Lombardo Riccardo, Mastroianni Riccardo, Collura Devis, Muto Giovanni, Gallucci Michele, Tubaro Andrea
BACKROUND: Recently metabolic syndrome has been associated to an increased risk of advanced disease. Aim of our study is to investigate the association of metabolic syndrome (MetS) with the risk of prostate cancer (PCa) upgrading and upstaging after radical prostatectomy (RP). METHODS: From 2012 and 2016, 400 consecutive men underwent RP at three referral centers in Italy and were enrolled into a prospective database. Blood pressure, body mass index and waist circumference were measured before RP...
June 4, 2018: Prostate Cancer and Prostatic Diseases
Landon C Brown, Guru Sonpavde, Andrew J Armstrong
BACKGROUND: Intermediate endpoints are needed in early phase studies of men with metastatic castration-resistant prostate cancer (mCRPC) that can reliably predict success in phase 3 trials. Among men with measurable disease, objective response may provide information as to whether a treatment is likely to be successful. METHODS: We conducted a systematic review of systemic agents that have proceeded to phase 3 trials in men with mCRPC and examined the relationship between improvements in measurable disease response in phase 2 trials and successful phase 3 trials leading to regulatory approval...
June 1, 2018: Prostate Cancer and Prostatic Diseases
Behfar Ehdaie, Sigrid Carlsson
No abstract text is available yet for this article.
June 1, 2018: Prostate Cancer and Prostatic Diseases
Manish Kohli, Jian Li, Meijun Du, David W Hillman, Scott M Dehm, Winston Tan, Rachel Carlson, Michael B Campion, Liguo Wang, Liewei Wang, Huijuan Zhang, Peng Zhang, Deepak Kilari, Chiang-Ching Huang, Liang Wang
BACKGROUND: The prognostic significance of plasma cell-free DNA (cfDNA) androgen receptor amplification (ARamp) in metastatic castration-resistant prostate cancer (mCRPC) compared with circulating tumor cell (CTC) counts is not known. METHODS: As part of correlative aims of a prospective study in mCRPC, concurrent and serial collections of plasma and CTCs were performed. Specimen collections were performed at baseline after progression on androgen deprivation therapy and then 12 weeks later...
June 1, 2018: Prostate Cancer and Prostatic Diseases
Karthik V Giridhar, Cristobal Sanhueza, David W Hillman, Hassan Alkhateeb, Rachel Carlson, Winston Tan, Brian A Costello, Fernando Quevedo, Lance Pagliaro, Manish Kohli
OBJECTIVE: To determine the prognostic value of serum chromogranin-A (CGA) in a two-cohort study of men with metastatic castrate resistant prostate cancer (mCRPC) and to compare with circulating tumor cells (CTCs)-based prognosis. PATIENTS AND METHODS: A two-cohort-based evaluation for serum CGA for prognostication in CRPC stage was performed using a screening cohort of 256 men with mCRPC and an independent validation cohort of 92 men with mCRPC. In both cohorts, men receiving proton pump inhibitors and those with non-castrate levels of testosterone (>50 ng/dl) were excluded...
June 1, 2018: Prostate Cancer and Prostatic Diseases
Corey M Porter, Eva Shrestha, Lauren B Peiffer, Karen S Sfanos
BACKGROUND: The human microbiome may influence prostate cancer initiation and/or progression through both direct and indirect interactions. To date, the majority of studies have focused on direct interactions including the influence of prostate infections on prostate cancer risk and, more recently, on the composition of the urinary microbiome in relation to prostate cancer. Less well understood are indirect interactions of the microbiome with prostate cancer, such as the influence of the gastrointestinal or oral microbiota on pro- or anti-carcinogenic xenobiotic metabolism, and treatment response...
May 23, 2018: Prostate Cancer and Prostatic Diseases
Roman Ganzer, Vinodh Kumar Adithyaa Arthanareeswaran, Hashim U Ahmed, Andrea Cestari, Pascal Rischmann, Georg Salomon, Dogu Teber, Evangelos Liatsikos, Jens-Uwe Stolzenburg, Eric Barret
BACKGROUND: With growing interest in focal therapy (FT) of prostate cancer (PCa) there is an increasing armamentarium of treatment modalities including high-intensity focused ultrasound (HIFU), cryotherapy, focal laser ablation (FLA), irreversible electroporation (IRE), vascular targeted photodynamic therapy (VTP), focal brachytherapy (FBT) and stereotactic ablative radiotherapy (SABR). Currently there are no clear recommendations as to which of these technologies are appropriate for individual patient characteristics...
May 9, 2018: Prostate Cancer and Prostatic Diseases
Huah Shin Ng, Bogda Koczwara, David Roder, Agnes Vitry
BACKGROUND: The increasing use of androgen deprivation therapy has prompted further evaluation of its potential adverse effects as the treatment may exacerbate or increase the risk of developing new comorbid diseases. This study aims to assess the patterns of comorbidities among Australian men with prostate cancer treated with androgen deprivation therapy. METHODS: Pharmaceutical Benefits Scheme (PBS) 10% data between 1 January 2003 and 31 December 2014 was utilised in this retrospective cohort study...
May 2, 2018: Prostate Cancer and Prostatic Diseases
Jennifer Mancio, Cátia Leal, Marta Ferreira, Pedro Norton, Nuno Lunet
BACKGROUND: Recent studies suggested that the relation between night-shift work and prostate cancer may differ between rotating and fixed schedules. OBJECTIVES: We aimed to quantify the independent association between night-shift work and prostate cancer, for rotating and fixed schedules. METHODS: We searched MEDLINE for studies assessing the association of night-shift work, by rotating or fixed schedules, with prostate cancer. We computed summary relative risk (RR) estimates with 95% confidence intervals (95% CI) using the inverse variance method and quantified heterogeneity using the I2 statistic...
April 27, 2018: Prostate Cancer and Prostatic Diseases
M M Cherrier, D J Cross, C S Higano, S Minoshima
OBJECTIVE: Androgen deprivation therapy (ADT) is a common treatment option for men with biochemical relapse from prostate cancer. ADT is associated with changes in mood, cognition, and quality of life, and most recently with increased risk for Alzheimer's disease (AD). This study examined changes in brain metabolism using positron emission tomography (PET) in men undergoing intermittent ADT. METHODS: Nine men with prostate cancer and a rising PSA (biochemical recurrence) without evidence of metastases were treated with intermittent ADT consisting of 9 months of complete androgen blockade achieved with combined leuprolide acetate and flutamide...
April 27, 2018: Prostate Cancer and Prostatic Diseases
M Samarinas, M Gacci, A de la Taille, S Gravas
BACKGROUND: The purpose of this narrative review is to evaluate the role of prostatic inflammation as a treatment target for lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO) and provide an update on the available therapies. METHODS: An extensive literature search was conducted for studies on established and investigational treatments with anti-inflammatory mechanism of action that has been assessed for the management of male LUTS due to BPO...
April 24, 2018: Prostate Cancer and Prostatic Diseases
W Demark-Wahnefried, S Rais-Bahrami, R A Desmond, J B Gordetsky, M Azrad, A D Frugé, E S Yang, L A Norian, W E Grizzle
No abstract text is available yet for this article.
April 24, 2018: Prostate Cancer and Prostatic Diseases
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"